Valneva (VALN) is developing a Lyme disease vaccine currently in stage 3 trials with 70% efficacy, positioned to capitalize on rising tick populations and a 40% increase in Lyme disease cases this year. Key risks include vaccine approval uncertainty, competition, and efficacy rate may be insufficient for market adoption.